What Is Aardvark Therapeutics, Inc. (AARD) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Aardvark Therapeutics, Inc.'s intrinsic value is estimated at $2.37. Trading at its current price of $6.67, the valuation engine raises significant caution: 8 of 9 models flag downside risk, projecting an average implied return of -64.5%. Notably, FTNN sees the most upside at +11.3% (fair value: $7.42), while Bayesian DCF is the most conservative at -97.8% ($0.15). The spread between these extremes — +109.0% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About AARD?
9 of 13 models are currently active for AARD. Of these, 1 model suggests upside while 8 models suggest overvaluation. The Bayesian DCF estimates AARD's intrinsic value at $0.15, implying -97.8% downside from the current price. See which stocks rank higher →
How Does AARD Rank in Biotechnology?
Among 76 Biotechnology stocks, AARD ranks #27 by Quality of Company score. CirclFi's QOC score of 5.5/10 evaluates 32 fundamental signals. A score of 5.5 reflects mixed fundamentals.
See all Most Undervalued Biotechnology Stocks →
The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For Aardvark Therapeutics, Inc., metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.
Is AARD a Value Trap?
The Value Trap algorithm is not active for AARD. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Aardvark Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Aardvark Therapeutics, Inc. scores 5.5 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +109.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every AARD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across AARD's 9 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad